Ledermann, Jonathan A
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Bennett, Bryan
Parry, David
Spencer, Stuart
Mann, Helen
Matulonis, Ursula
Article History
Received: 9 February 2016
Revised: 23 September 2016
Accepted: 30 September 2016
First Online: 8 November 2016
Competing interests
: JAL has participated in an advisory board for AstraZeneca. PH has acted in an advisory role for AstraZeneca and received honoraria from AstraZeneca. CG has acted in an advisory role for AstraZeneca, Clovis, Roche and Nucana, received honoraria from AstraZeneca and Roche, and received research funding from AstraZeneca, Novartis and Aprea. MF has participated in advisory boards for AstraZeneca, Clovis, Pfizer and Roche and received honoraria from AstraZeneca, Pfizer and Roche. IV has acted in an advisory role for AstraZeneca. GR has participated in advisory boards for AstraZeneca and Clovis. CS has acted in an advisory role for AstraZeneca, Clovis and Eisai Australia, received honoraria from AstraZeneca and Roche, provided expert testimony on behalf of AstraZeneca and received remuneration for travel from AstraZeneca. RS-F has participated in an advisory board for AstraZeneca. TS has acted in an advisory role for AstraZeneca and Clovis and received honoraria from AstraZeneca and Clovis. DM has acted in an advisory role for AstraZeneca and received honoraria from AstraZeneca. AF, DP, SS and HM are employees of AstraZeneca and own stock. UM has acted in an advisory role for AstraZeneca and Tesaro. All remaining authors declare no conflicts of interest.